A Clinical Exploratory Study of YOLT-204 in the Treatment of Hemoglobinopathies

The requested reference [9a2f516fef88698421aa785239c6e7b422c53b0e] no longer exists in our database. It has been replaced by the current reference: [ef79fb3499bc49bca85e2a028f2049f6d5beb4c6]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a single-arm, open-label, dose-escalation study designed to enroll approximately 5-30 patients with TDT or SCD. The objectives are to evaluate the safety and tolerability in patients following intravenous administration of YOLT-204 and to preliminarily assess its effect on fetal hemoglobin levels in plasma. In this study, the maximum screening period of the main study is 60 days, the treatment day is Day 0 (D0), and the safety follow-up period is up to Week 52 after administration.
Epistemonikos ID: 8fbc588778053d9f009a15d5711cd0a39a680029
First added on: Aug 19, 2026